Hilton Grand Vacations (NYSE:HGV) Stock

Hilton Grand Vacations

Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.

Earnings

Mid Cap

News

Markets

Analyst Ratings

Trading Ideas

MSGS

WYNN

Wynn Resorts, Limited (NASDAQ: WYNN) is scheduled to release second-quarter 2024 results on Aug 6, 2024, after the closing bell. In the previous quarter, the company delivered an earnings surprise of 11.2%.

Wynn Resorts Gears Up for Q2 Earnings: What&#39;s in Store?

Price Target

Hilton Grand Vacations (NYSE: HGV) closed the last trading session at $43.49, gaining 10.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide.

How Much Upside is Left in Hilton Grand Vacations? Wall Street Analysts Think 31.64%

Earnings Beats

NCLH

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is slated to report second-quarter 2024 results on Jul 31, before the opening bell.

In the last quarter, the company&#39;s earnings topped the Zacks Consensus Estimate by 33.3%, while revenues missed the same by 2%.

Here&#39;s What to Expect From Norwegian Cruise&#39;s Q2 Earnings

Hilton Grand Vacations Inc

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) sees FY2025 sales of $96.000 million-$98.000 million vs $97.72 million analyst estimate.

Guidance

LUNG

Pulmonx Sees FY2025 Sales $96.000M-$98.000M vs $97.72M Est

GRI's common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025
LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=MzcPI4Nne-gM9Y7IcrvoQNVonsr-sxSgaMIIl8GMorqA_B5Lg8fWbPdlBY6JIGy97U4a6Zc22KT2nbZICLkmUw==">GRI Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a&nbsp;1-for-17 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on February 11, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 21, 2025. The Company's common stock will open for trading under a new CUSIP number 3622AW 403 on The Nasdaq Capital Market on February 24, 2025, on a split-adjusted basis under the current ticker symbol "GRI." The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Stock Split

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Announces 1-For-17 Reverse Stock Split, Expected To Begin Trading On A Post-Split Adjusted Basis On February 24, 2025

The company's SEMVision&#x2122; H20 system combines the industry's most sensitive electron beam (eBeam) technology with advanced AI image recognition to enable better and faster analysis of buried nanoscale defects in the world's most advanced chips.

AMAT

Applied Materials Unveils New Chip Defect Review System

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) is looking for Q1 GAAP EPS of $(0.26)-$0.04 vs $0.72 analyst estimate..

Rogers Sees Q1 GAAP EPS $(0.26)-$0.04 vs $0.72 Est

WIIM

INSG

Inseego shares are trading lower. The company reported Q4 financial results.

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) is looking for Q1 Adj EPS of $0.10-$0.40 vs $0.72 analyst estimate. sees sales of $180.000 million-$195.000 million vs $200.20 million analyst estimate.

Rogers Sees Q1 Adj EPS $0.10-$0.40 vs $0.72 Est; Sees Sales $180.000M-$195.000M vs $200.20M Est

Broadstone Net Lease Sees FY25 AFFO $1.45-$1.49 Vs $1.52 Est.

Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 60.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $9.72 million which beat the analyst consensus estimate of $8.77 million by 10.79 percent. This is a 31.65 percent increase over sales of $7.38 million the same period last year.

ENVX

Enovix Q4 Adj EPS $(0.11) Beats $(0.18) Estimate, Sales $9.72M Beat $8.77M Estimate

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.45) by 26.67 percent. This is a 8.33 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $23.77 million which beat the analyst consensus estimate of $22.29 million by 6.61 percent. This is a 23.28 percent increase over sales of $19.28 million the same period last year.

Pulmonx Q4 EPS $(0.33) Beats $(0.45) Estimate, Sales $23.77M Beat $22.29M Estimate

Teekay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TK#NYSE">TK</a>) reported quarterly earnings of $0.19 per share. This is a 45.71 percent decrease over earnings of $0.35 per share from the same period last year. The company reported $256.57 million in sales this quarter. This is a 24.36 percent decrease over sales of $339.19 million the same period last year.

Teekay Q4 Adj EPS $0.19 Down From $0.35 YoY, Sales $256.57M Down From $339.19M YoY

<h4>Key Takeaways:</h4>
<ul>
<li>iMotion Automotive raised HK$228 million through new share placement, three months after raising a smaller HK$73 million</li>
<li>Last month the company entered a strategic tie-up with Horizon Robotics aimed at speeding up sales of its intelligent driving solutions into mass-produced vehicles</li>
</ul>
The surprising release of DeepSeek, a low-cost Chinese AI model, has sent companies racing to integrating the technology into their ecosystems, hoping it will work magic not only for their business but also their stocks.
One group catching the DeepSeek fever is intelligent driving, where the technology promises to improve existing products at far lower costs than previously thought. One such company is&nbsp;iMotion Automotive Technology (Suzhou) Co. Ltd.&nbsp;(1274.HK), whose stock is up 90% over the past month after it entered a strategic cooperation agreement with intelligent driving chip maker&nbsp;Horizon Robotics&nbsp;(9660.HK).
iMotion seized on the rally to raise HK$228 million ($28 million) through a new share placement earlier this month, with 60% of proceeds earmarked for developing high-level autonomous driving and integrated cockpit solutions and products. The fundraising was iMotion&rsquo;s second in the 14 months since its IPO, following one in early December where it raised a smaller HK$73.28 million. Only around HK$11.21 million in funds currently remain from that last fundraising, showing just how quickly iMotion is burning through its cash.
Word of the latest share sale brought iMotion exactly what it was hoping for. After initially dropping nearly 10% at one point on the day of the announcement, the stock powered back and ultimately closed up 4.2% for the day, pushing its valuation to HK$5.77 billion. The company began stoking up its cash pile just a few days earlier with its completion of the float of around 100 million unlisted H-shares on Feb. 6.
Under the latest fundraising, the company planned to issue up to 11.19 million shares to six or more underwriters, representing 4.63% of its enlarged share capital, according to&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0209/2025020900087.pdf">its announcement</a>. At HK$20.88 per share, the placement price represented a discount of about 13% to the HK$24 closing price the day before the announcement. But it was 18.57% higher than the stock&rsquo;s average closing price over the previous five trading days, and 35.06% higher than the previous 20 trading days, showing just how quickly the stock has risen.
<h4>Horizon Robotics collaboration</h4>
iMotion has popped up on investor radar screens as it enters a new high-speed growth stage. Last month, it formed a strategic tie-up with Horizon Robotics that will see the pair co-develop mass-produced intelligent driving solutions based on Horizon&rsquo;s Journey 6E series of chips. iMotion&rsquo;s products have also reportedly been selected exclusively for use in a new model being developed by Geely New Energy, based on Horizon&rsquo;s Journey 6 chip series.
Horizon&rsquo;s Journey 6E chips are among the most cost-efficient computing chips in the intelligent driving space, able to support functions such as high-speed navigation, autonomous parking and city memory navigation at a competitive cost of less than 5,000 yuan for the full suite.
The Horizon collaboration allows iMotion to target the middle end of the intelligent driving market whose vehicles typically sell for between 100,000 yuan ($13,800) and 150,000 yuan. Cars in that range account for 60% to 70% of annual car sales and are highly sought by intelligent driving companies trying to commercialize their products.
<h4>DeepSeek era dawning</h4>
While the Horizon tie-up is bringing real business potential, DeepSeek is also charging up intelligent driving and other automotive stocks with its potential to boost the sector. Since the Lunar New Year, more than 20 automakers, including Geely, Chery, Dongfeng, Great Wall, FAW-Volkswagen and SAIC-GM have begun using the DeepSeek model in their systems, showing the intelligent auto industry has entered a &ldquo;DeepSeek era.&rdquo;
iMotion has also been gearing up for the integration. According to sources familiar with the situation, it has used DeepSeek to test over 200 video clips, achieving solid outcomes and enhanced efficiency. Cars equipped with such DeepSeek technology can achieve more precise target identification, scenario understanding and path planning at the vehicle perception level, ensuring the stable and safe performance of their autonomous driving systems when confronted with complex road conditions. Moreover, DeepSeek&rsquo;s powerful model training and optimizing capabilities also help to improve algorithms and shorten product iteration cycles, thus improving the performance and stability of autonomous driving systems.
iMotion technology systems director Zhang Wei said in a media interview that &ldquo;to put it simply, DeepSeek enables city autonomous driving functions with the same level of performance but with much cheaper training and less data.&rdquo;
iMotion is still running on a capital-intensive model as it competes in a sector where heavy R&amp;D spending is a must and competition to get your products into new mass-produced vehicles is cutthroat. In terms of price-to-sales (P/S) ratio, iMotion stands at 4.4 times, higher than&nbsp;Huizhou Desay SV Automotive&rsquo;s&nbsp;(002920.SZ)&rsquo;s 2.7 times but much lower than the 32 for&nbsp;Black Sesame&nbsp;(2533.HK) and 8.7 times for&nbsp;Mobileye&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbly#NASDAQ">MBLY</a>), indicating the stock has yet to really take off despite its recent rally. That means the stock could have big upside potential if the company can roll out market-defining products that ultimately end up in mass-produced smart cars.
The Chinese intelligent driving technology market is still in its early stages, meaning anyone could still emerge on top if their products prove popular and reliable. With car makers such as XPeng, Nio and Li Auto all on the fast track to deploying intelligent driving technologies, speeding up R&amp;D and enhancing competitiveness are top priorities for not only iMotion but also its peers as they seek to get their products into the latest models. The arrival of DeepSeek and more breakthroughs for large AI models is adding more pressure on companies to differentiate their products and use the latest developments to their advantage. Otherwise, they could risk getting left behind the dust.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

MBLY

iMotion Automotive rides DeepSeek fever to new fundraising

Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.37 by 2.7 percent. This is unchanged from the same period last year. The company reported quarterly sales of $112.130 million which beat the analyst consensus estimate of $110.595 million by 1.39 percent. This is a 6.79 percent increase over sales of $105.000 million the same period last year.

Earnings Misses

Broadstone Net Lease Q4 2024 FFO $0.36 Misses $0.37 Estimate, Sales $112.130M Beat $110.595M Estimate

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.43 by 6.98 percent. This is a 23.33 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $192.20 million which beat the analyst consensus estimate of $191.75 million by 0.23 percent. This is a 6.06 percent decrease over sales of $204.60 million the same period last year.

Rogers Q4 Adj $0.46 Beats $0.43 Estimate, Sales $192.20M Beat $191.75M Estimate

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.22 by 63.64 percent. This is a 28.57 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $1.20 billion which beat the analyst consensus estimate of $1.19 billion by 0.47 percent. This is a 1.23 percent decrease over sales of $1.22 billion the same period last year.

Herbalife Q4 2024 Adj EPS $0.36 Beats $0.22 Estimate, Sales $1.20B Beat $1.19B Estimate

Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) reported quarterly sales of $48.09 million which beat the analyst consensus estimate of $45.57 million by 5.53 percent. This is a 12.47 percent increase over sales of $42.75 million the same period last year.

Inseego Q4 Sales $48.09M Beat $45.57M Estimate

TFII

FTI International shares are trading lower following worse-than-expected Q4 financial results.

Tanger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>) is looking for FY2025 FFO of $2.22-$2.30 vs $2.23 analyst estimate..

Tanger Sees FY2025 FFO $2.22-$2.30 vs $2.23 Est

2025 Full-Year Financial Guidance (in millions, except % and EPS amounts)
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Item</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="5" rowspan="1">2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenues (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3,100</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">to</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3,200</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Operating Margin % (2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">32&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">to</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">33&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Diluted EPS (2)(3)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$4.20</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">to</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$4.40</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $950 million.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1">Refer to Non-GAAP Information beginning on page 10&nbsp;of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(3)</td>
<td colspan="1" rowspan="1">Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding.</td>
</tr>
</tbody>
</table>
</figure>
BioMarin will host a conference call and webcast to discuss fourth quarter and full-year 2024 financial results today, Wednesday, February&nbsp;19, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at&nbsp;www.biomarin.com.

BMRN

BioMarin Pharmaceutical Sees FY25 Adj. EPS $4.20-$4.40 Vs $3.04 Est.; Revenue $3.1B-$3.2B Vs $3.105B Est.

Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.07 by 28.57 percent. This is a 171.43 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $1.34 billion which beat the analyst consensus estimate of $1.31 billion by 2.03 percent. This is a 29.15 percent increase over sales of $1.04 billion the same period last year.

TOST

Toast Q4 EPS $0.05 Misses $0.07 Estimate, Sales $1.34B Beat $1.31B Estimate

BioMarin Pharma shares are trading higher after the company reported better-than-expected Q4 financial results.

Press Releases

Hilton Grand Vacations Reports Third Quarter 2024 Results

Hilton Grand Vacations Completes $500 Million Term Securitization

Hilton Grand Vacations Announces Upsized and Consolidated $850 Million Warehouse Facility

Hilton Grand Vacations Partners With Boys & Girls Clubs of Central Florida for Youth Golf Clinic Program With World Long Drive Champion Maurice Allen

NBC's Dylan Dreyer, Award-Winning Actor Don Cheadle, NBA All-Star Blake Griffin and Pro Football Hall of Famer Charles Woodson to Play in 2025 Hilton Grand Vacations Tournament of Champions

Lydia Ko, Nelly Korda, Haeran Ryu, Brooke Henderson, Lauren Coughlin and More Compete in 2025 Hilton Grand Vacations Tournament of Champions

Hilton Grand Vacations Refinances Credit Facility and Term Loans

Hilton Grand Vacations Announces New Partnership with Operation Homefront

A Lim Kim Wins 2025 Hilton Grand Vacations Tournament of Champions, NHL Icon Joe Pavelski Crowned Celebrity Winner

Hilton Grand Vacations to Report Fourth Quarter and Full Year 2024 Results

Airbnb

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Booking Holdings

Choice Hotels International, Inc. Common Stock

Choice Hotels Intl

Despegar.com

Expedia Group

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Gr

Hyatt Hotels Corporation Class A Common Stock

Hyatt Hotels

Hilton Worldwide Holdings Inc. Common Stock

Hilton Worldwide Holdings

H World Group Limited - American Depositary Shares

H World Group

Intercontinental Hotels Group American Depositary Shares (Each representing one Ordinary Share)

Comments

Hilton Grand Vacations

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga